anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind 15 mg primaquine (PQ) from Day 1 to Day 14 and matched-placebo for tafenoquine (TQ) on Day 1.
During the Induction phase, participants will receive JNJ-73763989 subcutaneously along with JNJ-56136379 tablet orally with NA (either tenofovir disoproxil or tenofovir alafenamide tablets orally) treatment. At the start of consolidation phase, participants will be randomized to receive PegIFN-alpha-2a subcutaneously in addition to JNJ-73763989 and JNJ-56136379 with NA in arm 1 and arm 2 (without PegIFN-alpha-2a). According to predefined criteria NA treatment may be continued during the follow up (FU) phase.
Hydromorphone Hydrochloride, USP, a hydrogenated ketone of morphine, is an opioid agonist.

Hydromorphone Hydrochloride Oral Solution, USP is supplied as 5mg/ 5 mL (1 mg/mL) viscous liquid.

The chemical name is 4,5α-epoxy-3-hydroxy-17-methylmorphinan-6-one hydrochloride. The molecular Weight is 321.80. Its molecular formula is C17H19NO3·HCl, and it has the following chemical structure:

Hydromorphone Hydrochloride, USP is a white or almost white crystalline powder that is freely soluble in water, sparingly soluble in alcohol, practically insoluble in ether.

Each 5 mL (1 teaspoon) of Hydromorphone Hydrochloride Oral Solution, USP contains 5 mg of Hydromorphone Hydrochloride. The inactive ingredients are purified water, methylparaben, propylparaben, sucrose, and glycerin. Hydromorphone Hydrochloride Oral Solution may contain traces of sodium metabisulfite.
Comprehensive study, prospective, monocentric and cohort study.

Biventricular pacing is an effective therapy to improve end stage heart failure patients, however up to 30% of patients are unresponsive to this therapy. Among others, optimization of Left Ventricle (LV) pacing site location is critical to optimize response to Cardiac Resynchronization Therapy (CRT). Whether a better comprehension of baseline LV electrical activation can help to determine optimal LV lead location remains to be investigated.

After informed consent patients are included in the sudy. Day 1: CRT device is implanted under general anesthesia in a conventional fashion. The coronary sinus leads will be implanted guided by the acute hemodynamic response (+(dP/dt)max) using a RADI guide wire. After device implantation, a steerable mapping catheter will be inserted in the LV cavity to build a tridimensional activation map of the LV. This map will be obtained with and without CRT. From these maps different parameters describing LV activation will be measured and compared between patients with and without CRT. Quantitative parameters: Global LV activation time (LVATG) (primary outcome); septal activation time (LVTAS); Global intra-LV dispersion time and Qualitative parameters: presence of intraLV line of block, area of late activation. Day 5±2: A non-invasive map of the LV will be recorded with the CardioInsight ® system with and without CRT. The same parameters will be measured and compared with those obtained with invasive mapping. A 3 and 6 months follow-up visit including clinical, biological evaluation (NYHA status, 6-min walking test, BNP) of the patients will be performed with an additional transthoracic echocardiography at 6 months.
Adequate anticoagulation is achieved in cardiac surgery and interventional cardiology procedures with intravenous (IV) administration of unfractionated heparin. The Activated clotting time (ACT) is routinely measured to assess adequacy of anticoagulation to prevent clotting/thrombotic complications from placement of foreign materials used during cardiac surgery and cardiology procedures. Alternative methods to measure adequacy of anticoagulation such as measurement of Anti-Xa level and Reaction (R) time as assessed by Thromboelastrography (TEG) have also been suggested. However, their use in clinical practice is limited by lack of Point of Care (POC) technology and need for additional expertise to run these tests.

The efficiency and promptness of heparin anticoagulation is necessary during the structural heart procedures to minimize time from insertion of cannulae to valve deployment in cardiac surgery. The time required to prevent major complications is on the order of seconds to minutes. The goal of this study is to determine how rapidly the adequacy of heparin induced anticoagulation occurs using two different point of care ACT technologies (iSTAT and Hemochron). It is hypothesized that anticoagulation can be determined by the iSTAT ACT device 30 seconds after administration of heparin. Measuring heparin effectiveness at 30 or 90 seconds instead of the usual 3-minute time period may allow for earlier cardiac intervention.
Participants will undergo training sessions at the hospital. The exercise program will be individualized and guided by trained physiotherapists, for 3 months completion, aiming at 2-3 sessions a week (27 to 40 sessions in total), each lasting 45-60 minutes.
Participants with rheumatoid arthritis in Colombia, for whom the treating physician has decided to treat with golimumab prior to enrolment. All participants will be observed for 24 months. Any changes including addition of new medications or dose modifications of existing medications will be entirely according to the treating physician's judgment.
FIELD: medicine. SUBSTANCE: this method prescribes exposing infant patient to effect of pulse current on frontoorbital region in combination with administering metoclopramide at pulse current frequency of 800 to 100 Hz and strength sufficient to cause sensation of vibration under electrodes. Procedure duration: 20 to 40 min. Cure period: 10 to 15 procedures to be performed daily. EFFECT: minimization of side effects of medicinal preparations, reduction of hospital treatment period and prevention of progradient progress of process. 2 tbl
The utility model discloses a pre-filling injection agent, and relates to the field of pharmaceutical preparations. A pre-potting injector is adopted as a container for the prostaglandin and the derivative injection agent thereof. A needle-free pre-potting injector adopts the structure that an opening is formed at the rear end of an outer sleeve 1, and a rubber sleeve 5 for sealing a port is mounted on a front end conical head; and a piston 2 is connected with a push rod 3. A need type pre-potting injector adopts the structure that an opening is formed at the rear end of the outer sleeve 1, a protective cap 5 is sleeved on the front end conical head, a needle head 4 is coaxially mounted on the protective cap 5, and the piston 2 is connected with the push rod 3. The volume of the outer sleeve 1 ranges from 1 ml to 5 ml. The prostaglandin and the derivatives thereof include injections such as the prostaglandin, carboprost tromethamine, beraprost sodium, iloprost, latanoprost, bimatoprost, travoprost, dinoprost, misoprostol and the like. The utility model reduces drug residue, is accurate in dosage, and avoids the risk of recontamination to medicine wrapped by a common ampoule or a vial during the suction process, thereby enhancing the safety of a patient.
Catheter ablation (CA) is an essential method for the interventional treatment of atrial fibrillation (AF), and it is very important to reduce long-term recurrence after CA. The mechanism of recurrence after CA is still unclear. We established a long-term model of beagle canines after circumferential pulmonary vein ablation (CPVA). The transcriptome and proteome were obtained using high-throughput sequencing and TMT-tagged LC-MS/LC analysis, respectively. Differentially expressed genes and proteins were screened and enriched, and the effect of fibrosis was found and verified in tissues. A downregulated protein, neuropeptide Y (NPY), was selected for validation and the results suggest that NPY may play a role in the long-term reinduction of AF after CPVA. Then, the molecular mechanism of NPY was further investigated. The results showed that the atrial effective refractory period (AERP) was shortened and fibrosis was increased after CPVA. Atrial myocyte apoptosis was alleviated by NPY intervention, and Akt activation was inhibited in cardiac fibroblasts. These results suggest that long-term suppression of NPY after CPVA may lead to induction of AF through promoting cardiomyocyte apoptosis and activating the Akt pathway in cardiac fibroblasts, which may make AF more likely to reinduce.
PURPOSE:To provide the titled plaster having excellent slow-releasing effect of drug, composed of a substrate and a pressure-sensitive adhesive layer containing specific hollow fiber filled with a specific drug in the hollow part and having spaces at the circumference of said hollow fiber. CONSTITUTION:A volatile drug (e.g. nitric acid ester, halothane, chloral hydrate, guaiazulene, etc.) is filled in a hollow part of a hollow fiber (e.g. woven fabric, knit fabric, nonwoven fabric, polyester, etc.) having through-holes along circumferential direction. The objective slow-releasing plaster for transcutaneous administration is composed of a pressure-sensitive adhesive layer containing the above hollow fibers leaving spaces around the fiber and a substrate (e.g. polyolefin, polyester, etc.) supporting said adhesive layer. The plaster enables sure and slow administration of a drug at a required rate over a long period with a small application area preventing side effects such as stuffiness, rash, etc. The adhesive layer may be covered with a releasing sheet or incorporated with an absorbefacient.
BACKGROUND: Acute myocarditis usually presents as chest pain with rising troponin and normal coronary arteries. Despite frequent favourable evolution at the acute phase, it is associated with heart failure and ventricular rhythm disorders, and is considered the leading cause of sudden cardiac death in young, apparently healthy, adults. There are no specific recommendations for acute myocarditis diagnosis and management, only expert consensus, given the lack of large databases.
AIM: The main objective is to describe the contemporary presentation of acute myocarditis, its management and in-hospital outcomes. Secondary objectives are to investigate survival and event-free survival for up to 10years of follow-up, the determinants of prognosis, the modalities of treatment and follow-up and the gaps between expert consensus and real-life management.
METHODS: MyocarditIRM is a prospective multicentre cohort that enrolled 803 consecutive patients with acute myocarditis in 49 participating centres in France between 01 May 2016 and 28 February 2019. The diagnosis of acute myocarditis was acknowledged by cardiac magnetic resonance, using the Lake Louise Criteria. Exclusion criteria were age<18years, lack of health coverage, contraindication to cardiac magnetic resonance and refusal to participate. Detailed information was collected prospectively, starting at admission. Cardiac magnetic resonance imaging (diagnosis and follow-up) is analysed centrally by the certified core laboratory IHU ICAN. Ten years of follow-up for each patient is ensured by linking with the French National Health Database, and includes information on death, hospital admissions, major clinical events and drug consumption.
CONCLUSION: This prospective cohort with long-term follow-up represents the largest database on acute myocarditis worldwide, and will improve knowledge about its presentation, management and outcomes.
Itraconazole is rapidly absorbed after oral administration. Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following an oral capsule dose. The observed absolute oral bioavailability of itraconazole is about 55%.

The oral bioavailability of itraconazole is maximal when itraconazole capsules are taken immediately after a full meal. Absorption of itraconazole capsules is reduced in subjects with reduced gastric acidity, such as subjects taking medications known as gastric acid secretion suppressors (e.g., H 2-receptor antagonists, proton pump inhibitors) or subjects with achlorhydria caused by certain diseases (see PRECAUTIONS: Drug Interactions). Absorption of itraconazole under fasted conditions in these subjects is increased when itraconazole capsules are administered with an acidic beverage (such as a non-diet cola). When itraconazole capsules were administered as a single 200-mg dose under fasted conditions with non-diet cola after ranitidine pretreatment, a H 2-receptor antagonist, itraconazole absorption was comparable to that observed when itraconazole capsules were administered alone (see PRECAUTIONS: Drug Interactions). 

Itraconazole exposure is lower with the capsule formulation than with the oral solution when the same dose of drug is given (see WARNINGS).
NEW MATERIAL:A dimethylaniline derivative of formula I. USE:Useful as a cell differentiation-inducing examination reagent and a carcinogenic agent. Since the compound exhibits a strong cell differentiation-inducing activity in a low concentration and has a low cellular toxicity, the compound can be utilized for the clarification of cellular differentiation mechanism and carcinogenesis mechanism. The compound can be readily manufactured in large amounts. Orally or parenterally administrable. PREPARATION:A grignard reagent of formula II is reacted with glutaric anhydride in a ratio of 1:1-1:10, preferably 1:1-1:2, and the prepared carboxylic acid is esterified into methyl ester thereof. The prepared ester of formula III is reacted with hydroxylamine in the presence of a based to prepare the compound of formula I.
Introduction: Widely used diagnostic tests do not provide information to distinguish the pulp inflammation stage while improvement of materials, techniques and vital pulp therapy have received a wider acceptance in symptomatic pulpitis treatment. The aim of this clinical study was to compare MMP-9 expression in healthy and inflamed pulp and to assess the short-term outcome of coronal pulpotomy in mature permanent teeth with symptomatic pulpitis.

Methods: Patients diagnosed with symptomatic pulpitis were included in this clinical study. Coronal pulpotomy was performed using calcium-silicate based material and blood samples were taken. Initial and postoperative pain was recorded by Heft-Parker visual analog scale at 24 hours and 72 hours after the procedure. In control group teeth with healthy pulp were used. During follow-up visits after three and six-months, patients were examined clinically and radiographically. The ELISA kit was used to determine the levels of MMP-9 in inflamed and healthy coronal pulp tissue.
Long term studies in animals have not been performed to evaluate the carcinogenic potential of carisoprodol. 

Carisoprodol was not formally evaluated for genotoxicity. In published studies, carisoprodol was mutagenic in the in vitro mouse lymphoma cell assay in the absence of metabolizing enzymes, but was not mutagenic in the presence of metabolizing enzymes. Carisoprodol was clastogenic in the in vitro chromosomal aberration assay using Chinese hamster ovary cells with or without the presence of metabolizing enzymes. Other types of genotoxic tests resulted in negative findings. Carisoprodol was not mutagenic in the Ames reverse mutation assay using S.typhimurium strains with or without metabolizing enzymes, and was not clastogenic in an in vivo mouse micronucleus assay of circulating blood cells. Carisoprodol was not formally evaluated for effects on fertility. Published reproductive studies of carisoprodol in mice found no alteration in fertility although an alteration in reproductive cycles characterized by a greater time spent in estrus was observed at a carisoprodol dose of 1200 mg/kg/day. In a 13-week toxicology study that did not determine fertility, mouse testes weight and sperm motility were reduced at a dose of 1200 mg/kg/day. In both studies, the no effect level was 750 mg/kg/day, corresponding to approximately 2.6 times the human equivalent dosage of 350 mg four times a day, based on a body surface area comparison. 

The significance of these findings for human fertility is not known.
The invention discloses an effect of a voltage-gated proton channel Hv1 protein in the generation process of allergic asthma, and discloses a good mouse model for the allergic asthma, belonging to the field of medicine. By studying the Hv1 protein, we found that the level of allergic airway inflammation in Hv1 knockout mice (KO) was significantly higher after sensitization and stimulation with Ovalbumin (OVA) than in control, i.e. with allergic asthma conditions, compared to wild-type C57(WT) mice. After examination of serum, bronchoalveolar lavage (BALF) and lung tissue pathology, we found that the deficiency in Hv1 significantly promoted OVA-induced inflammatory cell recruitment, increasing Th2 cytokine levels and mucus secretion production in allergic asthmatic mice. Further experiments found that the lack of Hv1 significantly reduced the expression of NOXs, and these results indicate that the Hv1 knock-out increased the prevalence of allergic asthma by inhibiting ROS production. Aiming at the function of Hv1, the preparation method can be used for preparing a medicament for preventing, relieving and/or treating allergic asthma.
PROBLEM TO BE SOLVED: To obtain a cosmetic emulsion free from heavy feeling to the skin, effective for preventing the drying of skin and free from stickiness by combining isoparaffin with a sterol and a phosphatide and compounding the components to an oil and water at specific ratios. SOLUTION: This oil and water cosmetic emulsion contains about 0.1-20 wt.% of isoparaffins, about 0.001-0.8 wt.% (especially about 0.1-0.3 wt.%) of sterols and about 0.001-0.8 wt.% (especially about 0.1-0.3 wt.%) of phosphatides. The system may be incorporated further with about 0.01-10 wt.% of 8-22C alkylphosphate salts or about 0.1-20 wt.% of 16-22C alkanoic acid triglycerides. The sterol is preferably cholesterol, stigmasterol, sitosterol, ergosterol and their combination. Sunflower seed oil is preferable as the triglyceride and lecithin is preferable as the phosphatide. The amount of water in the emulsion is preferably about 50-95 wt.%.
Many circulating proteins are associated with risk of ESKD, but their source and the biological pathways/disease processes they represent are unclear. Using OLINK proteomics platform, concentrations of 455 proteins were measured in plasma specimens obtained at baseline from 399 individuals with diabetes. Elevated concentrations of 46 circulating proteins were associated (P < 1 × 10-5) with development of ESKD (n = 143) during 7-15 years of follow-up. Twenty of these proteins enriched apoptosis/TNF receptor signaling pathways. A subset of 20 proteins (5-7 proteins), summarized as an apoptosis score, together with clinical variables accurately predicted risk of ESKD. Expression of genes encoding the 46 proteins in peripheral WBCs showed no difference between cells from individuals who did or did not develop ESKD. In contrast, plasma concentration of many of the 46 proteins differed by this outcome. In single-nucleus RNA-Seq analysis of kidney biopsies, the majority of genes encoding for the 20 apoptosis/TNF receptor proteins were overexpressed in injured versus healthy proximal tubule cells. Expression of these 20 genes also correlated with the overall index of apoptosis in these cells. Elevated levels of circulating proteins flagging apoptotic processes/TNF receptor signaling pathways - and likely originating from kidney cells, including injured/apoptotic proximal tubular cells - preceded the development of ESKD.
We present a case of bilateral endogenous endophthalmitis with an extremely rare etiology of Capnocytophaga canimorsus. A 42-year-old asplenic patient with bilateral deterioration of visual acuity presented to the Emergency Department. The sudden deterioration of visual acuity, which prompted the patient to visit the ophthalmologist, was the first sign of the onset of sepsis. The physicians' attention, in addition to poor visual acuity and intense inflammation on ophthalmologic examination, was drawn to the reported flu-like symptoms. They were accompanied by high C-reactive protein results and abnormalities in echocardiography. A blood culture isolated the bacterium Capnocytophaga canimorsus. Immunocompromised patients are particularly susceptible to C. canimorsus infection. Endophthalmitis of this etiology has a very aggressive course, both ophthalmic and systemic. Therefore, quick diagnosis and initiation of adequate therapy are crucial.
Despite the notion that human CD8 +  T cells are the final mediators of autoimmune β-cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by β cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies. Inflammatory cytokines increased β-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known β-cell antigens and several insulin granule proteins. PCSK2 was identified as a novel β-cell antigen, which was processed into HLA-A2-restricted epitopes recognized by circulating naïve CD8 +  T cells in type 1 diabetic and healthy donors. Accordingly, the present invention relates to antigenic peptides derived from PCSK2 and uses thereof for the diagnosis and treatment of T1D.
Acute kidney injury (AKI) is commonly seen in infants diagnosed with hypoxic-ischemic encephalopathy (HIE) and is associated with increased rates of morbidity and mortality. Currently, there are no approved therapies that target the prevention of AKI. Several small trials in infants with HIE suggest that a single dose of theophylline given soon after birth attenuates the development of AKI. However, these studies were not performed in infants being treated with therapeutic hypothermia (the current standard of care for moderate to severe HIE), and only reported short-term outcomes. Therefore, few clinicians use theophylline in the management of these patients. The long-term goal is to undertake an appropriately powered multicenter clinical trial to test the hypothesis that for infants \> 35 weeks gestation treated with therapeutic hypothermia for HIE, intravenous theophylline (or aminophylline) within the first 18 hours after birth will result in a decreased incidence and/or severity of AKI or death (composite primary outcome) and improved long-term (2 year) renal outcomes. Before the conduct of a large trial, the feasibility of implementing the intervention and ability to measure relevant clinical outcomes need to be demonstrated. Therefore, the investigators propose a small pilot and feasibility clinical trial to i) evaluate recruitment, protocol adherence, and data collection procedures in a therapeutic trial of theophylline to decrease the incidence of AKI or death compared to standard treatment in infants with HIE being treated with therapeutic hypothermia; ii) evaluate the utility and applicability of established measures (serum creatinine, urine output, fluid balance) and novel, exploratory approaches to identify AKI in infants; and iii) determine theophylline pharmacokinetic, pharmacodynamic, safety and preliminary effectiveness profiles of two different theophylline dosing regimens in a therapeutic trial of theophylline to decrease the incidence of AKI or death compared to standard treatment. Using a mixed methods data analysis strategy to assess the research and intervention process and examine outcomes of the intervention, the investigators will generate the requisite data to inform development and implementation of an appropriately powered study to determine whether theophylline attenuates the risk and severity of AKI in infants with HIE treated with therapeutic hypothermia.